Residency · Residency · Neurology
Parkinson Disease: Advanced Therapies
Overview
After the "honeymoon period" of relatively stable levodopa response (typically 3-5 years), most PD patients develop motor complications. Motor fluctuations and dyskinesias affect approximately 50% of patients after 5 years and nearly all after 10 years of levodopa therapy. Advanced therapies become necessary when oral medication optimization alone is insufficient to manage these complications.
Motor Complications
Wearing Off (End-of-Dose Deterioration)
Wearing off is the most common motor complication and manifests as a predictable return of parkinsonian symptoms before the next levodopa dose is due. It results from progressive loss of dopaminergic neurons, which reduces the striatum's capacity to buffer dopamine levels. Pulsatile stimulation of postsynaptic receptors leads to altered receptor sensitivity over time. Wearing off manifests as both motor symptoms (stiffness, slowness, tremor return) and non-motor symptoms (anxiety, pain, mood changes).
On-Off Fluctuations
On-off fluctuations are unpredictable, sudden transitions between "on" states (when medication is working) and "off" states (when parkinsonian symptoms return). They may occur independently of the levodopa dosing schedule and are more disabling than predictable wearing off because patients cannot anticipate or plan around them.
Dyskinesia
Peak-dose dyskinesia consists of choreiform movements during peak levodopa effect and is the most common type. Diphasic dyskinesia occurs at the beginning and end of a dose cycle, is often dystonic in character, and preferentially involves the legs. Off-period dystonia is painful, often involves the foot, and is common in the early morning before the first levodopa dose.
Dose Failure and Delayed On
These phenomena relate to erratic gastric emptying and competition with dietary protein at the blood-brain barrier. A protein redistribution diet, concentrating protein intake at the evening meal, may help some patients.
<image>Timeline diagram showing the progression from stable levodopa response to wearing off, on-off fluctuations, and dyskinesia over years of treatment</image>
Oral Medication Optimization
Strategies for Wearing Off
Increasing levodopa frequency with smaller, more frequent doses is the simplest approach. Adding a COMT inhibitor (entacapone or opicapone) extends the half-life of levodopa. Adding a MAO-B inhibitor (rasagiline or safinamide) provides additional adjunctive benefit. Adding a dopamine agonist provides more continuous dopaminergic stimulation. Extended-release carbidopa-levodopa (Rytary) can produce more stable plasma levels.
Strategies for Dyskinesia
Amantadine, particularly in its extended-release formulation (Gocovri), is the only oral medication with a demonstrated anti-dyskinetic effect. Reducing individual levodopa doses may help but risks worsening wearing off. Replacing some of the levodopa with a dopamine agonist can also reduce peak-dose dyskinesia.
Deep Brain Stimulation (DBS)
Targets
| DBS Target | Primary Benefit | Levodopa Reduction | Best Candidate |
|---|---|---|---|
| STN (subthalamic nucleus) | Improves all cardinal motor features | 30-50% reduction | Standard candidate with motor fluctuations |
| GPi (globus pallidus internus) | Directly suppresses dyskinesia | Less reduction needed | Patients with cognitive concerns; prominent dyskinesia |
| VIM (ventral intermediate nucleus) | Tremor suppression | None | Tremor-dominant PD (less commonly used as primary target) |
The subthalamic nucleus (STN) is the most common DBS target for PD. It improves all cardinal motor features and allows significant levodopa dose reduction, typically 30-50%. The globus pallidus internus (GPi) directly suppresses dyskinesia, requires less levodopa reduction, and may be preferred in patients with cognitive concerns. The ventral intermediate nucleus (VIM) of the thalamus is primarily a tremor target and is less commonly used as the primary DBS target for PD.
Patient Selection
Appropriate candidates have motor complications refractory to oral optimization, spending more than 2 hours per day in a troublesome off state or experiencing more than 2 hours per day of functionally limiting dyskinesia. Good levodopa responsiveness (more than 30% improvement on a levodopa challenge test) is essential because this predicts the DBS response for STN and GPi targets. Significant cognitive impairment is an absolute contraindication, as is significant untreated psychiatric disease. Patients must have realistic expectations about what DBS can and cannot achieve.
EARLYSTIM Trial
The EARLYSTIM trial compared STN-DBS to best medical therapy in patients with early motor complications (mean disease duration approximately 7.5 years). DBS proved superior in quality of life, motor function, and activities of daily living at 2 years. This trial shifted the paradigm toward earlier consideration of DBS rather than waiting for severe disability. However, the average age at surgery was 52, and results may not generalize to elderly patients.
Programming Basics
Directional leads allow current steering to maximize efficacy and minimize side effects. Stimulation frequency is typically 130 Hz with pulse widths of 60-90 microseconds, and voltage or current is titrated to effect. Adaptive (closed-loop) DBS is an emerging technology that adjusts stimulation in real time based on local field potentials, particularly beta oscillations associated with the parkinsonian state.
<image>Coronal MRI section showing bilateral DBS lead placement in the subthalamic nucleus with surrounding anatomical structures labeled</image>
Levodopa-Carbidopa Intestinal Gel (LCIG / Duopa)
Mechanism and Delivery
LCIG provides continuous jejunal infusion of levodopa-carbidopa gel via a PEG-J tube. By delivering levodopa directly to the jejunum, it achieves steady-state plasma levels and reduces the pulsatile stimulation that drives motor complications. The standard regimen is a 16-hour daytime infusion, though select patients may benefit from 24-hour delivery.
Efficacy
LCIG reduces off time by approximately 2-4 hours per day compared to optimized oral levodopa. It also reduces dyskinesia severity by providing more continuous dopaminergic stimulation. The GLORIA registry demonstrated sustained benefit at 24 months.
Complications
Device-related issues include tube kinking, disconnection, stoma site infections, and peritonitis. Polyneuropathy has been reported, possibly related to vitamin B12 and B6 deficiency from chronic high-dose levodopa; these vitamin levels should be monitored. The therapy carries high cost and maintenance burden.
Subcutaneous Therapies
Subcutaneous Apomorphine
Apomorphine is available as intermittent injections (pen device) for rescue therapy during predictable off episodes, with onset of action in 10-20 minutes. Continuous subcutaneous infusion via pump provides continuous dopaminergic stimulation, reducing both off time and dyskinesia. Premedication with trimethobenzamide prevents nausea. Side effects include skin nodules at injection sites, orthostatic hypotension, and somnolence. The apomorphine pump is widely used in Europe and the UK.
Subcutaneous Foslevodopa-Foscarbidopa (Vyalev)
This therapy provides continuous 24-hour subcutaneous infusion of levodopa and carbidopa prodrugs, eliminating the need for PEG-J tube placement. Phase 3 data show significant reduction in off time. Infusion site reactions are common but generally manageable.
Focused Ultrasound (MRgFUS)
MRI-Guided Focused Ultrasound Thalamotomy
MRgFUS offers an incisionless, unilateral VIM thalamotomy for tremor-dominant PD. It is approved for medication-refractory PD tremor. Advantages include no implanted hardware, no surgical wound, and same-day completion. Limitations include restriction to unilateral treatment only (bilateral procedures carry high risk of dysarthria and ataxia), inability to address bradykinesia or rigidity, and limited long-term durability data. Subthalamotomy and pallidotomy targets are under investigation.
Emerging and Investigational Therapies
Disease-Modifying Approaches
Alpha-synuclein immunotherapy with prasinezumab showed a signal on motor progression in the PASADENA trial, with confirmatory trials ongoing. GLP-1 receptor agonists represent another promising avenue: lixisenatide showed slowed motor progression in the LIXIPARK trial, and exenatide Phase 3 trials are underway. Gene therapy using AAV-based delivery of GAD to the STN and AADC to the putamen is in early-phase trials showing promise. Antisense oligonucleotides targeting LRRK2 and SNCA are being developed for genetic forms of PD.
Cell-Based Therapies
iPSC-derived dopaminergic neuron transplantation is in early clinical trials. Historical fetal cell transplantation showed variable results, with the complication of graft-induced dyskinesia limiting enthusiasm until newer approaches matured.
<image>Comparison diagram of advanced PD therapies showing DBS, LCIG via PEG-J, subcutaneous apomorphine pump, and focused ultrasound with their respective advantages and limitations</image>
Clinical Pearls
The levodopa challenge test is essential before DBS referral: a patient who does not respond to levodopa will not respond to STN or GPi DBS, with the exception of tremor, which may respond even without robust levodopa responsiveness. Consider referral for advanced therapy when a patient spends more than 1-2 hours per day in a troublesome off state or has functionally limiting dyskinesia despite oral optimization. Morning dystonia often responds to a bedtime dose of controlled-release carbidopa-levodopa or a long-acting dopamine agonist. Monitor for weight loss, B12 deficiency, and polyneuropathy in patients on high-dose levodopa or LCIG. DBS does not halt disease progression; symptoms that are not levodopa-responsive (freezing of gait, postural instability, dementia, dysarthria) will continue to worsen and eventually dominate the clinical picture. Cognitive screening with the MoCA should be performed before any surgical intervention, with a score below 26 warranting detailed neuropsychological testing.
References
- Schuepbach WMM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications (EARLYSTIM). N Engl J Med. 2013;368(7):610-622.
- Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141-149.
- Pagano G, Taylor KI, Anzures-Cabrera J, et al. Trial of prasinezumab in early-stage Parkinson's disease. N Engl J Med. 2022;387(5):421-432.
- Meissner WG, Remy P, Giordana C, et al. Trial of lixisenatide in early Parkinson's disease. N Engl J Med. 2024;390(13):1176-1185.
- Elias WJ, Lipsman N, Ondo WG, et al. A randomized trial of focused ultrasound thalamotomy for essential tremor. N Engl J Med. 2016;375(8):730-739.
